GlobeImmune Newswire

GlobeImmune Newswire

Comprehensive Real-Time News Feed for GlobeImmune.

Results 1 - 20 of 43 in GlobeImmune

  1. Woes continue for Louisville's GlobeImmune as CEO, board members exit companyRead the original story

    Tuesday Nov 22 | LongmontFYI

    The woes for GlobeImmune Inc. continue to mount as the Louisville biotech announced a series of changes last week that include the resignation of its chief executive officer and other key board members.

    Comment?

  2. Woes continue for Louisville's GlobeImmune as CEO, board members exit companyRead the original story w/Photo

    Tuesday Nov 22 | Daily Camera

    The woes for GlobeImmune Inc. continue to mount as the Louisville biotech announced a series of changes last week that include the resignation of its chief executive officer and other key board members. The company has also terminated the lease on its 40,000-square-foot headquarters at 1450 Infinite Drive in Louisville, according a statement by the company.

    Comment?

  3. After Kissing GlobeImmune Goodbye, Here are 2 Biotechs That Could be Next on Gilead's Hit ListRead the original story

    Monday Nov 21 | BioSpace

    Last week Gilead terminated its licensing deal with GlobeImmune to develop a hepatitis-B drug, GS-4774.

    Comment?

  4. What's Next At GlobeImmune Inc (GBIM)?Read the original story w/Photo

    Monday Nov 21 | Insider Monkey

    ... to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member. GlobeImmune Inc (OTCMKTS: GBIM ) shareholders did not have a good week last week. The company put out a press release outlining its latest ...

    Comment?

  5. Gilead Destroys GlobeImmune's HBV Dreams - Who's Next?Read the original story w/Photo

    Monday Nov 21 | Seeking Alpha

    Last week Gilead terminated its licensing deal with GlobeImmune to develop a hepatitis-B drug, GS-4774. Gilead also terminated its rights to GS-4774, which was returned to GlobeImmune: GlobeImmune, Inc. today provided an update on the Company's business: -- Gilead Sciences, Inc. has terminated the collaboration and license agreement with the Company and its rights to GS-4774 have been returned to GlobeImmune -- Timothy C. Rodell has resigned his positions as the Company's Chief Executive Officer and President but remains on the Board of Directors... GlobeImmune later terminated the lease for its 40,000 square foot office, laboratory and manufacturing facilities.

    Comment?

  6. Globeimmune looks to bite the dust in another failure from the IPO class of 2014Read the original story

    Sunday Nov 20 | BioWorld

    In a terse bulleted statement, Globeimmune Inc. disclosed what sounded like its death knell: dissolution of its license agreement with Gilead Sciences Inc. for hepatitis B virus candidate GS-4774 , wholesale resignation of the company's CEO and board and termination of its office and manufacturing space.

    Comment?

  7. Tuberculosis Pipeline Landscape and Global Therapeutics Market Review for H2 2016Read the original story w/Photo

    Sunday Nov 20 | PR Newswire

    ... Eli Lilly and Company, Ensol Biosciences Inc., EpiVax, Inc., FIT Biotech Oy, GangaGen Inc., GlaxoSmithKline Plc, Globeimmune, Inc., Hager Biosciences, LLC, Hsiri Therapeutics LLC, Imaxio SA, Immunitor, Inc., ImmunoBiology Limited, Inovio ...

    Comment?

  8. GlobeImmune future uncertain as more signs point to shutdownRead the original story

    Friday Nov 18 | The Boulder County Business Report

    Investor interest in Boulder apartments doesn't appear to be going anywhere any time soon. The high-end Solana 3100 New hospitals and standalone emergency rooms seem to be popping up in every corner of Northern Colorado and the Boulder FORT COLLINS - Chicago-based Core Spaces closed recently on the $5.65 million purchase of C.B. & Potts' West Elizabeth Street Robots in the surgical suite are nothing new, but robots assisting orthopedic surgeons on total knee replacements is groundbreaking.

    Comment?

  9. Struggles intensify for Louisville biotech GlobeImmuneRead the original story

    Friday Nov 18 | The Boulder County Business Report

    The struggles for GlobeImmune Inc. continue as the biotech announced a series of events Thursday that include the resignation of its CEO and key board members, and the termination of the lease on its 40,000-square-foot headquarters building at 1450 Infinite Drive in Louisville that had office, laboratory and manufacturing space. The company said Thursday it does not plan to publicly release any further information about its operations or business, leaving it unclear if GlobeImmune will be dissolved, acquired or if operations will be suspended.

    Comment?

  10. GlobeImmune Announces UpdatesRead the original story

    Thursday Nov 17 | World News Report

    Gilead Sciences, Inc. has terminated the collaboration and license agreement with the Company and its rights to GS-4774 have been returned to GlobeImmune; Timothy C. Rodell has resigned his positions as the Company's Chief Executive Officer and President but remains on the Board of Directors; C. Jeffrey Dekker has been appointed as the Company's President, Secretary and Treasurer and been named to the Company's Board of Directors; J. William Freytag, Augustine J. Lawlor, Dan J. Mitchell and S. Edward Torres have resigned from the Company's Board of Directors; and The Company has terminated the lease for 40,000 gross square feet of office, laboratory and manufacturing space which formerly served as the Company's corporate headquarters.

    Comment?

  11. BRIEF-GlobeImmune announces updatesRead the original story w/Photo

    Thursday Nov 17 | Reuters

    * GlobeImmune Inc says Timothy C. Rodell has resigned his positions as company's chief executive officer and president but remains on board of directors Nov 17 Apparel chain Gap Inc said it would shut more stores than forecast previously and that it ...

    Comment?

  12. GlobeImmune CEO Steps Down, Terminates HQ Lease and Gets Dumped by GileadRead the original story

    Thursday Nov 17 | BioSpace

    Gilead Sciences, Inc. has terminated the collaboration and license agreement with the Company and its rights to GS-4774 have been returned to GlobeImmune; Timothy C. Rodell has resigned his positions as the Company's Chief Executive Officer and President but remains on the Board of Directors; C. Jeffrey Dekker has been appointed as the Company's President, Secretary and Treasurer and been named to the Company's Board of Directors; J. William Freytag, Augustine J. Lawlor, Dan J. Mitchell and S. Edward Torres have resigned from the Company's Board of Directors; and The Company has terminated the lease for 40,000 gross square feet of office, laboratory and manufacturing space which formerly served as the Company's corporate headquarters.

    Comment?

  13. Gilead: Expect Focus On Products, Not AcquisitionsRead the original story w/Photo

    Oct 17, 2016 | Seeking Alpha

    ... filled with biotech gold to keep its stock price afloat, but that hasn't been the case. Partners such as GlobeImmune are working hard in the Hep B space as it may be the next big thing after Hep C to be solved from a patient treatment perspective. ...

    Comment?

  14. GlobeImmune bulls hopes hinge on 48-week data for GS-4774; shares up 5%Read the original story w/Photo

    Oct 3, 2016 | Seeking Alpha

    Thinly traded nano cap GlobeImmune inches up on modest volume, building on its uptrend that began on September 21. Shares have perked up 65% since then, stoked primarily over optimism over positive 48-week data from a Phase 2 study assessing GS-4774, a therapeutic HBV vaccine candidate being developed by Gilead Sciences . The results will be presented at The Liver Meeting in Boston on the afternoon of Monday, November 14. The abstract, #231 , describes the study assessing the combination of GS-4774 and TDF compared to TDF alone in 195 non-cirrhotic HBV-positive patients not on antiretroviral medication.

    Comment?

  15. GlobeImmune up 33% on hope of good news regarding HBV therapeutic vaccine at Liver MeetingRead the original story w/Photo

    Sep 26, 2016 | Seeking Alpha

    Thinly traded nano cap GlobeImmune perks up on 60% higher volume, albeit on turnover of only 187K shares, as investors take positions ahead of The Liver Meeting in Boston, November 11 - 15. An oral abstract has been selected for presentation in Parallel Session 35 on GS-4774, a therapeutic HBV vaccine candidate being developed by Gilead Sciences . Bulls perceive that acceptance of the paper, "Safety and Efficacy of GS-4774 in Combination with TDF in Patients with Chronic Hepatitis B not on Antiviral Medication," bodes well for long-term positive results from the current Phase 2 trial .

    Comment?

  16. Louisville's GlobeImmune delists from NasdaqRead the original story w/Photo

    Jul 9, 2016 | Denver Post

    Troubled GlobeImmune expects to delist from Nasdaq by July 25 because it cannot meet the minimum financial conditions required by the exchange. The Louisville-based biopharmaceutical company began restructuring last year, after poor results from clinical trials of its drug to treat hepatitis B. GlobeImmune now employs a single scientist and one financial officer full time.

    Comment?

  17. Louisville's GlobeImmune, struggling and down to 2 employees, delists from NasdaqRead the original story

    Jul 7, 2016 | LongmontFYI

    Officials at Louisville-based GlobeImmune Inc. announced Tuesday that after failing to find a buyer, the company will delist its stock from the NASDAQ exchange.

    Comment?

  18. 10 Biggest Mid-Day Losers For WednesdayRead the original story

    Jul 6, 2016 | Benzinga

    GlobeImmune Inc shares tumbled 40.4 percent to $1.07 after the company reported delisting and deregistration of common stock. Eagle Bulk Shipping Inc shares fell 16.1 percent to $0.365.

    Comment?

  19. Why Tesla, Apple, Alibaba, and Two Other Stocks Are Trending TodayRead the original story w/Photo

    Jul 6, 2016 | Insider Monkey

    ... in markets around the world. Among the stocks traders are talking about are Tesla Motors Inc (NASDAQ: TSLA ) , GlobeImmune Inc (NASDAQ:GBIM) , Apple Inc. (NASDAQ: AAPL ) , Alibaba Group Holding Ltd (NYSE: BABA ) , and Himax Technologies, Inc. (ADR) ...

    Comment?

  20. Mid-Morning Market Update: Markets Open Lower; Walgreens Profit Tops ExpectationsRead the original story

    Jul 6, 2016 | Benzinga

    ... gaining 38 percent to $86.41 after the company agreed to be acquired by Melrose Industries for $86.00 per share. GlobeImmune Inc (NASDAQ: GBIM ) shares dropped 39 percent to $1.10 after the company reported delisting and deregistration of common ...

    Comment?